Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis
- 31 March 2008
- journal article
- Published by Elsevier BV in Molecular Immunology
- Vol. 45 (5), 1470-1476
- https://doi.org/10.1016/j.molimm.2007.08.013
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathwayBlood, 2007
- The PD-1/PD-L pathway is up-regulated during IL-12-induced suppression of EAE mediated by IFN-gammaJournal of Neuroimmunology, 2007
- PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosisJournal of Hepatology, 2006
- Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cellsJCI Insight, 2006
- Adoptive immunotherapy for cancer: building on successNature Reviews Immunology, 2006
- Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significanceActa Histochemica, 2006
- The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic FactorsNeoplasia, 2006
- Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal CancerClinical Cancer Research, 2005
- Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activationNature, 2002
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationThe Journal of Experimental Medicine, 2000